3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
9
Metastatic Castration-resistant Prostate Cancer
2
Urogenital Neoplasms
1
Renal Insufficiency
1
Prostatic Neoplasms, Castration-Resistant
1
Prostatic Diseases
1
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
1
Neoplasms by Site
1
Neoplasms
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Metastatic Castration Resistant Prostate Cancer (mCRPC)
1
Metastatic Castration Resistant Prostate Cancer
1
Male Urogenital Diseases
1
Genital Neoplasms, Male
1
Interventions
Pemetrexed
10
Carboplatin
8
pembrolizumab
7
Cisplatin
7
130-nm albumin-bound paclitaxel
6
Paclitaxel
5
Nivolumab
5
Gemcitabine
5
ribociclib
4
palbociclib
4
napabucasin
4
durvalumab
4
Fulvestrant
4
Bevacizumab
4
osimertinib
3
abemaciclib
3
Mitomycin
3
Irinotecan
3
Fluorouracil
3
Drug Therapy
3
Anastrozole
3
Albumin-Bound Paclitaxel
3
AZD9833
3
selpercatinib
2
pralsetinib
2
patritumab
2
ficlatuzumab
2
exemestane
2
atezolizumab
2
Watchful Waiting
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Neoplasms by Site
×
Pluvicto
×
Clear all
NCT06785636
2026-04-24
P300
Pathos AI, Inc.
Phase 1/2
Recruiting
252 enrolled